BioConnection, ChemConnection, and Proxy announce successful release of the first Combidex batch.

BioConnection, ChemConnection and PROXY are honored to announce the successful release of the first batch of Combidex, a revolutionary product from the Radboudumc Department of Radiology and Nuclear Medicine initiated by Professor Jelle Barentsz.

This achievement was made under the lead and management of BioConnection. ChemConnection manufactured the API batch and PROXY, a wholly owned subsidiary of Sinenis LifeSciences, performed the formulation and product release.

The product is an important step forward in lymph node imaging enabling better cancer treatment. The cooperation shows the innovative power of the Dutch life sciences industry and University and combines state of the art chemistry, analytics and GMP manufacturing of high-tech nano-suspensions.

Professor Jelle Barentsz of the Radboudumc: “It was a great experience working with these high-tech Dutch companies. They were able to meet tight timelines and developed and manufactured this high-tech product beyond expectation. They succeeded where others failed. This product will open better ways for diagnostics of prostate- and other cancer. The cooperation of the three companies was unique, last but not least a result of the management by BioConnection, and the final result is fantastic”.

Dr. Alexander Willemse, CEO of BioConnection, also on behalf of Dr. Gerjan Kemperman, CEO of ChemConnection, and Dr. Ruud Santing, CEO of Sinensis LifeSciences : ‘The enthusiasm of Professor Jelle Barentsz pushed us forward. He was a good source of inspiration. The chemistry and analytics of this product are highly complex but by joining forces we were able to successfully develop and manufacture this product. It was a challenge for chemistry, analytics and fill & finish. We are very proud that we were able to release our first batch for human use and contribute to this breakthrough in cancer therapy’.

Source: BioConnection     

Afdrukken